BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.95% | -16.23% | -2.28% | -22.91% | 40.39% |
| Total Depreciation and Amortization | 61.15% | -13.50% | -54.08% | 278.23% | -1.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.60% | 32.73% | -62.07% | 35.51% | -77.21% |
| Change in Net Operating Assets | 102.31% | -833.96% | 105.10% | -615.88% | -76.14% |
| Cash from Operations | 58.66% | -69.39% | 34.42% | -132.23% | -41.54% |
| Capital Expenditure | -6,930.16% | -350.00% | -100.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -97.61% | 156.48% | -- | -- | -- |
| Cash from Investing | -155.70% | 155.95% | -194,471.43% | -- | -- |
| Total Debt Issued | 723.96% | 0.00% | 0.00% | -19.04% | 23.52% |
| Total Debt Repaid | -3.66% | 21.96% | -8.62% | -42.62% | -4.81% |
| Issuance of Common Stock | -- | -- | -- | 1,047.57% | 400.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,051.18% | 41.47% | -103.64% | 1,038.40% | 895.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -145.32% | 122.55% | -198.39% | 4,231.17% | 149.23% |